Perhaps the most promising new drug to be released on the market for RA is Actemra, also known as Tocilizumab. After 6 months of use 43% of people are in remission according to the DAS28 score. Another 30% has an ACR score of 70%. This is a fantastic new treatment and is expected for US approval in 2007. THis drug targets Interleukin-6...there is another company investigating the Interleukin-27, which is suppose to be even better. Reports from EULAR, which occured this past June, forecasts a medicated remission rate of 100% within the next ten years. Here is the link for the Actemra info.
http://www.docguide.com/news/content.nsf/news/852571020057CC F68525719A0063DAA3